UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000037558 |
|---|---|
| Receipt number | R000042822 |
| Scientific Title | Clinical trial on serum DHA concentration by consecutive ingestion of self-emulsifying formulation or nonself-emulsifying formulation contained DHA. A randomized, double-blind, crossover study. |
| Date of disclosure of the study information | 2019/08/01 |
| Last modified on | 2020/08/07 09:30:27 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Clinical trial on serum DHA concentration by consecutive ingestion of self-emulsifying formulation or nonself-emulsifying formulation contained DHA. A randomized, double-blind, crossover study.
Acronym
Clinical trial on serum DHA concentration by consecutive ingestion of self-emulsifying formulation or nonself-emulsifying formulation contained DHA.
Scientific Title
Clinical trial on serum DHA concentration by consecutive ingestion of self-emulsifying formulation or nonself-emulsifying formulation contained DHA. A randomized, double-blind, crossover study.
Scientific Title:Acronym
Clinical trial on serum DHA concentration by consecutive ingestion of self-emulsifying formulation or nonself-emulsifying formulation contained DHA.
Region
| Japan |
Condition
Condition
Healthy adult
Classification by specialty
| Adult |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
Investigation of difference in the absorption by a treatment of self-emulsification formulation contained DHA.
Basic objectives2
Pharmacokinetics
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
Serum DHA concentration
Before 1 week, 0 week, 1week, 2weeks
Key secondary outcomes
Serum EPA concentration
Before 1 week, 0 week, 1week, 2weeks
Base
Study type
Interventional
Study design
Basic design
Cross-over
Randomization
Randomized
Randomization unit
Individual
Blinding
Double blind -all involved are blinded
Control
Active
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
2
Purpose of intervention
Prevention
Type of intervention
| Food |
Interventions/Control_1
Ingestion of test food for 2 weeks
Interventions/Control_2
Ingestion of control food for 2 weeks
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| 65 | years-old | > |
Gender
Male
Key inclusion criteria
1. Age: 20 -65 years old
2. Sex : Male
3. BMI:18.5-30 kg/m2
4. Written informed consent
Key exclusion criteria
1. Patient with dyslipidaemia
2. Medical treatment for some diseases
3. Subjects with severe liver diseases, digestive organ diseases, kidney diseases and heart diseases
4. Sublects who are bleeding at present or danger of bleeding (serious injuries and operations, etc.)
5. Can't stop to take a supplement during the study period.
6. Difficulty in collecting blood.
7. Smoker
8. Subjects who are planned to participate in other clinical study.
9. Subjects who are judged as unsuitable for the study by the investigator for other reason.
Target sample size
60
Research contact person
Name of lead principal investigator
| 1st name | Kei |
| Middle name | |
| Last name | Yui |
Organization
FANCL Corporation
Division name
Research Institute, Health science research center
Zip code
244-0806
Address
12-13, Kamishinano, Totsuka-ku, Yokohama, Kanagawa
TEL
045-820-3755
ke-yui@fancl.co.jp
Public contact
Name of contact person
| 1st name | Reiko |
| Middle name | |
| Last name | Naito |
Organization
Kenkoin Medical Corporation Foundation
Division name
Kenkoin Clinic
Zip code
104-0061
Address
6-7-4 Ginza, Chuo-ku, Tokyo, Japan
TEL
03-3573-1153
Homepage URL
reiko-naito@kenkoin.jp
Sponsor or person
Institute
FANCL Corporation
Institute
Department
Personal name
Funding Source
Organization
FANCL Corporation
Organization
Division
Category of Funding Organization
Profit organization
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Research Ethics Committee of Kenkoin Medical Corporation Foundation
Address
6-7-4 Ginza, Chuo-ku, Tokyo, Japan
Tel
03-3573-1153
isamu-yanase@kenkoin.jp
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
医療法人財団健康院 健康院クリニック
Other administrative information
Date of disclosure of the study information
| 2019 | Year | 08 | Month | 01 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2019 | Year | 07 | Month | 16 | Day |
Date of IRB
| 2019 | Year | 07 | Month | 16 | Day |
Anticipated trial start date
| 2019 | Year | 08 | Month | 01 | Day |
Last follow-up date
| 2019 | Year | 11 | Month | 30 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2019 | Year | 07 | Month | 31 | Day |
Last modified on
| 2020 | Year | 08 | Month | 07 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000042822
